Clinical Trials Logo

Non-Rhabdo. Soft Tissue Sarcoma clinical trials

View clinical trials related to Non-Rhabdo. Soft Tissue Sarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04854018 Completed - Rhabdomyosarcoma Clinical Trials

Indo-cyanine Green (ICG) in Paediatric Oncology MIS

Start date: April 30, 2021
Phase: Phase 4
Study type: Interventional

Indo-cyanine green (ICG) is a dye that has been used for a variety of adult and paediatric uses since 1956. Over the past few years, near infrared (NIRF) technology has been developed which allow is use as a fluorescence agent during surgery. It has been used increasingly in the field of adult oncology surgery and has been shown to increase the efficacy of this surgery. The aim of this study is to evaluate the use of NIRF and ICG during specific minimally invasive surgery (MIS) procedures within paediatric oncology surgery. Their use will complement existing surgical techniques rather than replace them. Given the published advantages in adults this study aims to provide evidence of feasibility in the paediatric patients with cancer.

NCT ID: NCT03054792 Enrolling by invitation - Rhabdomyosarcoma Clinical Trials

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas

Start date: May 1, 2017
Phase: Phase 1
Study type: Interventional

This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI, Magnetic Resonance Spectroscopy (MRS) and 18F-FAZA PET-MRI with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (7-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.